Literature DB >> 31689494

Translational pathology, genomics and the development of systemic therapies for acral melanoma.

Yian Ann Chen1, Jamie K Teer2, Zeynep Eroglu3, Jheng-Yu Wu4, John M Koomen5, Florian A Karreth5, Jane L Messina3, Keiran S M Smalley6.   

Abstract

Acral melanomas arise on the non-hair bearing skin of the palms, soles and in the nail beds. These rare tumors comprise 2-3 % of all melanomas, are not linked to UV-exposure, and represent the most frequent subtype of melanomas in patients of Asian, African and Hispanic origin. Although recent work has revealed candidate molecular events that underlie acral melanoma development, this knowledge is not yet been translated into efficacious local, regional, or systemic therapies. In the current review, we describe the clinical characteristics of acral melanoma and outline the genetic basis of acral melanoma development. Further discussion is given to the current status of systemic therapy for acral melanoma with a focus on ongoing developments in both immunotherapy and targeted therapy for the treatment of advanced disease.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acral melanoma; Systemic therapies; Translational genomics

Mesh:

Substances:

Year:  2019        PMID: 31689494      PMCID: PMC7771370          DOI: 10.1016/j.semcancer.2019.10.017

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  99 in total

1.  KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.

Authors:  Abdlsattar Zebary; Katarina Omholt; Ismini Vassilaki; Veronica Höiom; Diana Lindén; Lisa Viberg; Lena Kanter-Lewensohn; Carolina Hertzman Johansson; Johan Hansson
Journal:  J Dermatol Sci       Date:  2013-08-08       Impact factor: 4.563

2.  A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Authors:  Clemens Krepler; Katrin Sproesser; Patricia Brafford; Marilda Beqiri; Bradley Garman; Min Xiao; Batool Shannan; Andrea Watters; Michela Perego; Gao Zhang; Adina Vultur; Xiangfan Yin; Qin Liu; Ioannis N Anastopoulos; Bradley Wubbenhorst; Melissa A Wilson; Wei Xu; Giorgos Karakousis; Michael Feldman; Xiaowei Xu; Ravi Amaravadi; Tara C Gangadhar; David E Elder; Lauren E Haydu; Jennifer A Wargo; Michael A Davies; Yiling Lu; Gordon B Mills; Dennie T Frederick; Michal Barzily-Rokni; Keith T Flaherty; Dave S Hoon; Michael Guarino; Joseph J Bennett; Randall W Ryan; Nicholas J Petrelli; Carol L Shields; Mizue Terai; Takami Sato; Andrew E Aplin; Alexander Roesch; David Darr; Steve Angus; Rakesh Kumar; Ensar Halilovic; Giordano Caponigro; Sebastien Jeay; Jens Wuerthner; Annette Walter; Matthias Ocker; Matthew B Boxer; Lynn Schuchter; Katherine L Nathanson; Meenhard Herlyn
Journal:  Cell Rep       Date:  2017-11-14       Impact factor: 9.423

3.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

4.  Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.

Authors:  Guilian Niu; Tammy Bowman; Mei Huang; Steve Shivers; Douglas Reintgen; Adil Daud; Alfred Chang; Alan Kraker; Richard Jove; Hua Yu
Journal:  Oncogene       Date:  2002-10-10       Impact factor: 9.867

Review 5.  A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?

Authors:  Keiran S M Smalley
Journal:  Int J Cancer       Date:  2003-05-01       Impact factor: 7.396

6.  Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Authors:  K H T Paraiso; I V Fedorenko; L P Cantini; A C Munko; M Hall; V K Sondak; J L Messina; K T Flaherty; K S M Smalley
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

Review 7.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

8.  Acral melanoma. A clinicopathologic study of 28 patients.

Authors:  C S Lin; W J Wang; C K Wong
Journal:  Int J Dermatol       Date:  1990-03       Impact factor: 2.736

9.  Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.

Authors:  Vinicius de Lima Vazquez; Anna L Vicente; Adriana Carloni; Gustavo Berardinelli; Paula Soares; Cristovam Scapulatempo; Olga Martinho; Rui M Reis
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

10.  Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

Authors:  Henrik Schmidt; Stefan Suciu; Cornelis J A Punt; Martin Gore; Wim Kruit; Poulam Patel; Danielle Lienard; Hans von der Maase; Alexander M M Eggermont; Ulrich Keilholz
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

View more
  8 in total

1.  Cell position matters in tumour development.

Authors:  Jean-Christophe Marine; María S Soengas
Journal:  Nature       Date:  2022-04       Impact factor: 49.962

2.  Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.

Authors:  Jiannong Li; Inna Smalley; Zhihua Chen; Jheng-Yu Wu; Manali S Phadke; Jamie K Teer; Thanh Nguyen; Florian A Karreth; John M Koomen; Amod A Sarnaik; Jonathan S Zager; Nikhil I Khushalani; Ahmad A Tarhini; Vernon K Sondak; Paulo C Rodriguez; Jane L Messina; Y Ann Chen; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

3.  Characteristics, Prognosis, and Competing Risk Nomograms of Cutaneous Malignant Melanoma: Evidence for Pigmentary Disorders.

Authors:  Zichao Li; Xinrui Li; Xiaowei Yi; Tian Li; Xingning Huang; Xiaoya Ren; Tianyuan Ma; Kun Li; Hanfeng Guo; Shengxiu Chen; Yao Ma; Lei Shang; Baoqiang Song; Dahai Hu
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

4.  Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review.

Authors:  Qingyue Zheng; Jiarui Li; Hanlin Zhang; Yuanzhuo Wang; Shu Zhang
Journal:  Front Oncol       Date:  2020-12-03       Impact factor: 6.244

5.  Integration of Bulk RNA Sequencing and Single-Cell RNA Sequencing to Reveal Uveal Melanoma Tumor Heterogeneity and Cells Related to Survival.

Authors:  Guohong Gao; Aijun Deng; Shan Liang; Shengsheng Liu; Xinyi Fu; Xiaoyan Zhao; Zhilong Yu
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

6.  Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.

Authors:  Prachi Bhave; Tasnia Ahmed; Serigne N Lo; Alexander Shoushtari; Anne Zaremba; Judith M Versluis; Joanna Mangana; Michael Weichenthal; Lu Si; Thierry Lesimple; Caroline Robert; Claudia Trojanello; Alexandre Wicky; Richard Heywood; Lena Tran; Kathleen Batty; Florentia Dimitriou; Anna Stansfeld; Clara Allayous; Julia K Schwarze; Meghan J Mooradian; Oliver Klein; Inderjit Mehmi; Rachel Roberts-Thomson; Andrea Maurichi; Hui-Ling Yeoh; Adnan Khattak; Lisa Zimmer; Christian U Blank; Egle Ramelyte; Katharina C Kähler; Severine Roy; Paolo A Ascierto; Olivier Michielin; Paul C Lorigan; Douglas B Johnson; Ruth Plummer; Celeste Lebbe; Bart Neyns; Ryan Sullivan; Omid Hamid; Mario Santinami; Grant A McArthur; Andrew M Haydon; Georgina V Long; Alexander M Menzies; Matteo S Carlino
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

7.  Long Noncoding RNA LINC02249 Is a Prognostic Biomarker and Correlates with Immunosuppressive Microenvironment in Skin Cutaneous Melanoma.

Authors:  Maotao Du; Liang Han; Pan Shen; Dengyan Wu; Shenghao Tu
Journal:  J Oncol       Date:  2022-09-07       Impact factor: 4.501

Review 8.  Advanced Acral Melanoma Therapies: Current Status and Future Directions.

Authors:  Yiqun Zhang; Shijie Lan; Di Wu
Journal:  Curr Treat Options Oncol       Date:  2022-09-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.